RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Summary

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.

Timeline

Start

2020-12-02

Primary completion

2023-01-30

Completion

2023-06-06

Publications

• Dhakal B, Hari P, Chhabra S, Szabo A, Lum LG, Glass DD, Park JH, Donato M, Siegel DS, Felizardo TC, Fowler DH. Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma. J Immunother Cancer. 2025 Jan 28;13(1):e010649. doi: 10.1136/jitc-2024-010649.

Drugs

Indications